CHEMO PHARMA LABORATORIES LTD. - 506365 - Announcement under Regulation 30 (LODR)-Demise
DISCLOSURE OF EVENTS OR INFORMATION AS PER REG. 30 AND 68(2) OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 -SAD DEMISE OF SHRI. SHREENIWAS SOMANI, CEO AND WHOLE TIME DIRECTOR OF THE COMPANY Chemo Pharma Laboratories Ltd - 506365 - Submission Of Un-Audited Financial Results For The Quarter And Half Year Ended 30.09.2020
Submission of Un-Audited Financial Results for the quarter and half year ended 30.09.2020 CHEMO PHARMA LABORATORIES LTD. - 506365 - AUTHORISATION FOR DISCLOSURE OF EVENTS OR INFORMATION AS PER REGULATION 30 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (LODR)
AUTHORISATION FOR DISCLOSURE OF EVENTS OR INFORMATION AS PER REGULATION 30 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (LODR) CHEMO PHARMA LABORATORIES LTD. - 506365 - Submission Of Outcome Of Board Meeting Held On 19/10/2020 At 04 P.M.
Submission of Outcome of Board Meeting held on 19/10/2020 at 04 p.m. CHEMO PHARMA LABORATORIES LTD. - 506365 - Submission Of Certificate Pursuant To Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, Issued By M/S. HS Associates, Practising Company Secretary For The Half Year Ended 30Th September, 2020
Submission of Certificate pursuant to Regulation 40(9) of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, issued by M/s. HS Associates, Practising Company Secretary for the half year ended 30th September, 2020 CHEMO PHARMA LABORATORIES LTD. - 506365 - Shareholding for the Period Ended September 30, 2020
Chemo Pharma Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2020. For more details, kindly Click here CHEMO PHARMA LABORATORIES LTD. - 506365 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Submission of Certificate pursuant to Regulation 74 (5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter and half year ended 30th September, 2020 CHEMO PHARMA LABORATORIES LTD. - 506365 - Board Meeting Intimation for Intimation Of Board Meeting Scheduled On Monday, 19Th October, 2020 At 04:00 P.M. At The Corporate Office Of The Company
CHEMO PHARMA LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/10/2020 ,inter alia, to consider and approve Dear Sirs, This is to inform you that the Meeting of the Board of Directors of the Company will be held on Monday, 19th October, 2020 at 04:00 p.m. at the Corporate Office of the Company at Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400001 to transact the following business: 1.To consider and approve the Un-Audited Financial Results and Statement of Assets and Liability for the Quarter and Half year ended 30th September, 2020. 2.To place and take on record the Limited Review Report on Un-Audited Financial Results for the Quarter and Half year ended 30th September, 2020. 3.To consider and appoint Secretarial Auditor of the Company for the Financial Year 2020-2021. CHEMO PHARMA LABORATORIES LTD. - 506365 - Submission Of Compliance Certificate Pursuant To The Regulation 7(3) Of Securities Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 For Quarter And Half Year Ended 30Th September, 2020
Submission of Compliance Certificate Pursuant to the Regulation 7(3) of Securities Exchange Board of India (Listing Obligations and Disclosure requirements) Regulations, 2015 for Quarter and Half Year ended 30th September, 2020 CHEMO PHARMA LABORATORIES LTD. - 506365 - Statement Of Investor Complaints For The Quarter Ended September 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- ASHOK SOMANIDesignation :- Managing Director / Whole Time Director